JP2012505913A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505913A5 JP2012505913A5 JP2011532268A JP2011532268A JP2012505913A5 JP 2012505913 A5 JP2012505913 A5 JP 2012505913A5 JP 2011532268 A JP2011532268 A JP 2011532268A JP 2011532268 A JP2011532268 A JP 2011532268A JP 2012505913 A5 JP2012505913 A5 JP 2012505913A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- item
- alkoxy
- composition
- stream
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 67
- 239000000203 mixture Substances 0.000 claims description 57
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 239000002502 liposome Substances 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 239000013543 active substance Substances 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 13
- 206010017076 Fracture Diseases 0.000 claims description 8
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 8
- 206010014599 encephalitis Diseases 0.000 claims description 8
- 208000019622 heart disease Diseases 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 208000019423 liver disease Diseases 0.000 claims description 8
- 208000030159 metabolic disease Diseases 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 230000000692 anti-sense effect Effects 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- 238000009295 crossflow filtration Methods 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000010392 Bone Fractures Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 208000016097 disease of metabolism Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- -1 amino acid compounds Chemical class 0.000 claims description 3
- 239000008227 sterile water for injection Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 229940122498 Gene expression inhibitor Drugs 0.000 claims description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 2
- 239000012062 aqueous buffer Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000010791 quenching Methods 0.000 claims description 2
- 230000000171 quenching effect Effects 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 2
- 229930186217 Glycolipid Natural products 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 229940106189 ceramide Drugs 0.000 claims 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 2
- 229930183167 cerebroside Natural products 0.000 claims 2
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 150000002270 gangliosides Chemical class 0.000 claims 2
- 150000002327 glycerophospholipids Chemical class 0.000 claims 2
- 150000004678 hydrides Chemical class 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 2
- 125000000962 organic group Chemical group 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 150000003408 sphingolipids Chemical class 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 2
- 150000008575 L-amino acids Chemical group 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000014509 gene expression Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 108091030071 RNAI Proteins 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 101150102415 Apob gene Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10606208P | 2008-10-16 | 2008-10-16 | |
| US61/106,062 | 2008-10-16 | ||
| US16737909P | 2009-04-07 | 2009-04-07 | |
| US61/167,379 | 2009-04-07 | ||
| PCT/US2009/060930 WO2010045512A2 (en) | 2008-10-16 | 2009-10-16 | Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014251287A Division JP6126072B2 (ja) | 2008-10-16 | 2014-12-11 | 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012505913A JP2012505913A (ja) | 2012-03-08 |
| JP2012505913A5 true JP2012505913A5 (cg-RX-API-DMAC7.html) | 2012-11-22 |
Family
ID=41560381
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532268A Pending JP2012505913A (ja) | 2008-10-16 | 2009-10-16 | 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物 |
| JP2014251287A Active JP6126072B2 (ja) | 2008-10-16 | 2014-12-11 | 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014251287A Active JP6126072B2 (ja) | 2008-10-16 | 2014-12-11 | 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20100112042A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2902013A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2012505913A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20110071017A (cg-RX-API-DMAC7.html) |
| CN (2) | CN102231979B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2009305639B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0920171A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2739046A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL212329A0 (cg-RX-API-DMAC7.html) |
| SG (1) | SG196818A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010045512A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201102319B (cg-RX-API-DMAC7.html) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006259415B2 (en) | 2005-06-15 | 2012-08-30 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
| SI2494993T1 (sl) | 2007-05-04 | 2019-01-31 | Marina Biotech, Inc. | Aminokislinski lipidi in njihove uporabe |
| CA3006395C (en) | 2008-11-07 | 2022-05-31 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| WO2010059829A2 (en) * | 2008-11-19 | 2010-05-27 | Mdrna, Inc. | Compositions and methods for triggered release rna therapeutics |
| CN102665761A (zh) | 2009-11-04 | 2012-09-12 | 玛瑞纳生物技术有限公司 | 活性产生递送分子 |
| US20110244026A1 (en) | 2009-12-01 | 2011-10-06 | Braydon Charles Guild | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| EP2609135A4 (en) | 2010-08-26 | 2015-05-20 | Massachusetts Inst Technology | POLY (BETA AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF |
| JP6054308B2 (ja) * | 2011-02-15 | 2016-12-27 | メリマック ファーマシューティカルズ， インコーポレイテッドＭｅｒｒｉｍａｃｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 核酸を細胞へ送達する組成物及び方法 |
| PL2691443T3 (pl) | 2011-03-28 | 2021-08-30 | Massachusetts Institute Of Technology | Sprzężone lipomery i ich zastosowania |
| LT2717893T (lt) | 2011-06-08 | 2019-08-12 | Translate Bio, Inc. | Lipidų nanodalelių kompozicijos ir mrnr pristatymo būdai |
| AU2012308320C1 (en) * | 2011-09-14 | 2018-08-23 | Translate Bio Ma, Inc. | Multimeric oligonucleotide compounds |
| EP4074694A1 (en) | 2011-10-27 | 2022-10-19 | Massachusetts Institute Of Technology | Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof |
| SI2773326T1 (sl) * | 2011-11-04 | 2019-04-30 | Nitto Denko Corporation | Metoda za sterilno proizvodnjo delcev lipidno-nukleinske kisline |
| AU2013262700A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating hemoglobin gene family expression |
| CA2873794A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating smn gene family expression |
| WO2013173598A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating atp2a2 expression |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| EP2850185A4 (en) | 2012-05-16 | 2015-12-30 | Rana Therapeutics Inc | COMPOSITIONS AND METHOD FOR MODULATING UTRN GENE EXPRESSION |
| US20150152410A1 (en) | 2012-05-16 | 2015-06-04 | Rana Therapeutics, Inc. | Compositions and methods for modulating mecp2 expression |
| US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| WO2014028487A1 (en) | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| US20150247141A1 (en) | 2012-09-14 | 2015-09-03 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
| AU2014236305B2 (en) | 2013-03-14 | 2019-01-17 | Ethris Gmbh | CFTR mRNA compositions and related methods and uses |
| MX2015012865A (es) | 2013-03-14 | 2016-07-21 | Shire Human Genetic Therapies | Metodos para purificacion de arn mensajero. |
| CN103172701B (zh) * | 2013-03-18 | 2015-09-30 | 中国科学院过程工程研究所 | 一种新型穿膜肽及其应用 |
| US9745583B2 (en) | 2013-04-30 | 2017-08-29 | Delta-Fly Pharma, Inc. | Liposome for topical administration and application thereof |
| WO2014179562A1 (en) | 2013-05-01 | 2014-11-06 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
| CA2921161A1 (en) * | 2013-09-24 | 2015-04-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for the manufacture of lipid nanoparticles |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| EP3871696B1 (en) | 2013-10-22 | 2025-03-19 | Translate Bio, Inc. | Lipid formulations for delivery of messenger rna |
| ES2954366T3 (es) | 2013-10-22 | 2023-11-21 | Translate Bio Inc | Terapia de ácido ribonucleico mensajero para la deficiencia de argininosuccinato sintetasa |
| RS66380B1 (sr) | 2014-04-23 | 2025-02-28 | Modernatx Inc | Vakcine nukleinske kiseline |
| MX373952B (es) | 2014-04-25 | 2020-07-13 | Shire Human Genetic Therapies | Métodos de purificación de arn mensajero. |
| CN106659731A (zh) | 2014-05-30 | 2017-05-10 | 夏尔人类遗传性治疗公司 | 用于递送核酸的可生物降解脂质 |
| JP6599373B2 (ja) | 2014-06-24 | 2019-10-30 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 核酸の送達のための立体化学的に濃縮した組成物 |
| EP3164379A1 (en) | 2014-07-02 | 2017-05-10 | Massachusetts Institute of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
| JP5934848B1 (ja) * | 2014-10-30 | 2016-06-15 | Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 | 局所投与用リポプレックスの新規製造方法及び該リポプレックスを使用する抗腫瘍剤 |
| JP6373749B2 (ja) * | 2014-12-19 | 2018-08-15 | 富士フイルム株式会社 | リポソームの製造方法及びリポソーム製造装置 |
| SI3310764T1 (sl) | 2015-06-19 | 2023-06-30 | Massachusetts Institute Of Technology | Z alkenilom substituirani 2,5-piperazindioni in njihova uporaba v sestavkih za dostavo sredstva subjektu ali celici |
| WO2017031232A1 (en) * | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| JP6921833B2 (ja) | 2015-10-22 | 2021-08-18 | モデルナティーエックス， インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
| US9901649B2 (en) | 2016-05-03 | 2018-02-27 | International Business Machines Corporation | Block copolymers for therapeutic drug delivery |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| KR101797168B1 (ko) * | 2016-11-10 | 2017-11-13 | 주식회사 바이오셀트란 | 신규의 프로테인 트랜스덕션 도메인을 함유하는 구형 구조체 |
| US11253605B2 (en) | 2017-02-27 | 2022-02-22 | Translate Bio, Inc. | Codon-optimized CFTR MRNA |
| AU2018259859B2 (en) * | 2017-04-28 | 2024-02-15 | Kyowa Kirin Co., Ltd. | Oligonucleotide derivative or salt thereof |
| MA49138A (fr) | 2017-05-16 | 2020-03-25 | Translate Bio Inc | Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| CA3073211A1 (en) * | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| JP7256824B2 (ja) * | 2018-04-25 | 2023-04-12 | エスリス ゲーエムベーハー | 粒子状製剤用の凍結保護剤 |
| CN112930396B (zh) | 2018-08-24 | 2024-05-24 | 川斯勒佰尔公司 | 用于纯化信使rna的方法 |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| AU2019384557B2 (en) | 2018-11-21 | 2025-07-17 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR |
| WO2020154594A2 (en) * | 2019-01-25 | 2020-07-30 | Agenovir Corporation | Compositions and methods for treatment of human papillomavirus |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| JP7752615B2 (ja) * | 2019-12-20 | 2025-10-10 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの直腸送達 |
| EP3915544A1 (en) * | 2020-05-25 | 2021-12-01 | Leon-Nanodrugs GmbH | Method for producing a liposome dispersion |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US20240408034A1 (en) * | 2021-10-06 | 2024-12-12 | Leon-Nanodrugs Gmbh | Method for preparing lipid nanoparticles |
| CN114569703B (zh) * | 2022-02-25 | 2023-06-13 | 纽柏抗衰老国际医生集团(广州)有限公司 | 一种助睡眠的脂质体包裹复合氨基酸的组合物及制备方法 |
| CN116370437A (zh) * | 2023-05-26 | 2023-07-04 | 北京因诺惟康医药科技有限公司 | 包含胆固醇琥珀酸单酯的核酸脂质纳米颗粒组合物及其用途 |
| WO2025207519A1 (en) * | 2024-03-23 | 2025-10-02 | Texas Tech University System | Biocompatible and biodegradable polymer nanodiscs as lipoprotein-mimicking nanocarriers with high stability and long circulation time for drug delivery |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR8207733A (pt) | 1981-06-04 | 1983-05-10 | Pharmasol Corp | Recipiente pressurizado com bomba de suprimento |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| CH671514A5 (cg-RX-API-DMAC7.html) * | 1986-12-03 | 1989-09-15 | Induchem Ag | |
| US4778810A (en) | 1987-01-08 | 1988-10-18 | Nastech Pharmaceutical Co., Inc. | Nasal delivery of caffeine |
| CA1339303C (en) | 1987-09-21 | 1997-08-19 | Lyle John Arnold Jr. | Non-nucleotide linking reagents for nucleotide probes |
| US5563250A (en) | 1987-12-02 | 1996-10-08 | Neorx Corporation | Cleavable conjugates for the delivery and release of agents in native form |
| CA2039718C (en) | 1989-08-31 | 2003-02-25 | John J. Rossi | Chimeric dna-rna catalytic sequences |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5962219A (en) | 1990-06-11 | 1999-10-05 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-selex |
| DE552178T1 (de) | 1990-10-12 | 1994-02-03 | Max Planck Gesellschaft | Abgeänderte ribozyme. |
| DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| AU4769893A (en) | 1992-07-17 | 1994-02-14 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| PT748382E (pt) | 1993-09-02 | 2003-03-31 | Ribozyme Pharm Inc | Acidos nucleicos enzimaticos contendo nao-nucleotidos |
| AU8088694A (en) | 1993-10-27 | 1995-05-22 | Ribozyme Pharmaceuticals, Inc. | 2'-amido and 2'-peptido modified oligonucleotides |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US6447796B1 (en) | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| EP1179340A3 (en) | 1994-09-30 | 2003-05-07 | INEX Pharmaceutical Corp. | Compositions for the introduction of polyanionic materials into cells |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5681940A (en) | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
| US5716824A (en) | 1995-04-20 | 1998-02-10 | Ribozyme Pharmaceuticals, Inc. | 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes) |
| DE69634084T2 (de) * | 1995-06-07 | 2005-12-08 | Inex Pharmaceuticals Corp. | Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer |
| US6051429A (en) | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| JP4338106B2 (ja) | 1995-06-07 | 2009-10-07 | ライフ テクノロジーズ コーポレーション | ペプチド増強カチオン脂質トランスフェクション |
| US7422902B1 (en) * | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US7034009B2 (en) | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| EP0886641A2 (en) | 1996-01-16 | 1998-12-30 | Ribozyme Pharmaceuticals, Inc. | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6509320B1 (en) | 1996-10-16 | 2003-01-21 | Icn Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses thereof |
| DE69735382T2 (de) | 1996-11-04 | 2006-11-30 | Qiagen Gmbh | Kationische reagenzien zür transfektion |
| US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
| US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
| US5965542A (en) * | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
| US6835395B1 (en) * | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| US6110745A (en) * | 1997-07-24 | 2000-08-29 | Inex Pharmaceuticals Corp. | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
| US6734171B1 (en) * | 1997-10-10 | 2004-05-11 | Inex Pharmaceuticals Corp. | Methods for encapsulating nucleic acids in lipid bilayers |
| AU1922999A (en) | 1997-12-16 | 1999-07-05 | Baylor College Of Medicine | Needle-free injection of formulated nucleic acid molecules |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| DE69941447D1 (de) | 1998-01-05 | 2009-11-05 | Univ Washington | Erhöhter transport unter benutzung membranzerstörender stoffe |
| US6426086B1 (en) | 1998-02-03 | 2002-07-30 | The Regents Of The University Of California | pH-sensitive, serum-stable liposomes |
| CA2326823A1 (en) | 1998-04-20 | 1999-10-28 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| HRP20000751A2 (en) | 1998-05-26 | 2001-12-31 | Icn Pharmaceuticals | Novel nucleosides having bicyclic sugar moiety |
| CA2365625A1 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of substances to cells |
| US6849272B1 (en) | 1999-04-21 | 2005-02-01 | Massachusetts Institute Of Technology | Endosomolytic agents and cell delivery systems |
| US6083482A (en) | 1999-05-11 | 2000-07-04 | Icn Pharmaceuticals, Inc. | Conformationally locked nucleosides and oligonucleotides |
| US7098032B2 (en) | 2001-01-02 | 2006-08-29 | Mirus Bio Corporation | Compositions and methods for drug delivery using pH sensitive molecules |
| DK1102785T3 (da) | 1999-06-07 | 2013-05-13 | Arrowhead Res Corp | Sammensætninger til lægemiddeltilførsel ved anvendelse af pH-følsomme molekyler |
| AU769357B2 (en) | 1999-07-15 | 2004-01-22 | University Of British Columbia, The | Methods for preparation of lipid-encapsulated therapeutic agents |
| US7094423B1 (en) * | 1999-07-15 | 2006-08-22 | Inex Pharmaceuticals Corp. | Methods for preparation of lipid-encapsulated therapeutic agents |
| US6200599B1 (en) | 1999-10-07 | 2001-03-13 | The Regents Of The University Of California | Ortho ester lipids |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| EP1203614A1 (de) * | 2000-11-03 | 2002-05-08 | Polymun Scientific Immunbiologische Forschung GmbH | Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln |
| US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
| US6897196B1 (en) | 2001-02-07 | 2005-05-24 | The Regents Of The University Of California | pH sensitive lipids based on ortho ester linkers, composition and method |
| DE10109897A1 (de) * | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
| NZ528523A (en) | 2001-03-26 | 2006-03-31 | Alza Corp | Liposome composition for improved intracellular delivery of a therapeutic agent |
| EP1386004A4 (en) | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
| US20030077829A1 (en) * | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| US7141540B2 (en) | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| AU2003217550A1 (en) | 2002-02-20 | 2003-09-09 | Ribozyme Pharmaceuticals, Incorporated | RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| EP1509203B1 (en) * | 2002-05-15 | 2016-04-13 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
| ES2354607T3 (es) * | 2002-06-28 | 2011-03-16 | Protiva Biotherapeutics Inc. | Procedimiento y aparato para producir liposomas. |
| JP4951338B2 (ja) | 2003-07-16 | 2012-06-13 | プロチバ バイオセラピューティクス インコーポレイティッド | 脂質に封入された干渉ｒｎａ |
| EP1512393A1 (de) * | 2003-09-08 | 2005-03-09 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Verfahren zur Herstellung von homogenen Liposomen und Lipoplexen |
| ES2707393T3 (es) * | 2004-03-26 | 2019-04-03 | Curis Inc | Moduladores de interferencia de ARN de señalización de hedgehog y usos de los mismos |
| US7514530B2 (en) * | 2004-04-26 | 2009-04-07 | Centre National De La Recherche Scientifique | Peptide carrier for delivering siRNA into mammalian cells |
| US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
| AU2005247091B2 (en) * | 2004-05-24 | 2010-08-12 | Polymun Scientific Immunbiologische Forschung Gmbh | Superloaded liposomes for drug delivery |
| US20070213293A1 (en) | 2005-04-08 | 2007-09-13 | Nastech Pharmaceutical Company Inc. | Rnai therapeutic for respiratory virus infection |
| US20070213257A1 (en) * | 2005-08-12 | 2007-09-13 | Nastech Pharmaceutical Company Inc. | Compositions and methods for complexes of nucleic acids and peptides |
| US7579318B2 (en) * | 2005-12-06 | 2009-08-25 | Centre De La Recherche De La Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| EP2004141A2 (en) * | 2006-03-17 | 2008-12-24 | Novosom AG | An efficient method for loading amphoteric liposomes with nucleic acid active substances |
| US20080213350A1 (en) * | 2007-02-20 | 2008-09-04 | Texas Tech University System | Encapsulation of nucleic acids in liposomes |
| US20080299659A1 (en) | 2007-03-02 | 2008-12-04 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting apob gene expression and uses thereof |
| SI2494993T1 (sl) * | 2007-05-04 | 2019-01-31 | Marina Biotech, Inc. | Aminokislinski lipidi in njihove uporabe |
| NZ580712A (en) | 2007-05-22 | 2011-12-22 | Marina Biotech Inc | Hydroxymethyl substituted rna oligonucleotides and rna complexes containing acyclic monomers |
| JP5697450B2 (ja) * | 2007-10-02 | 2015-04-08 | マリーナ バイオテック，インコーポレイテッド | 核酸の送達のためのリポペプチド |
| US11625808B2 (en) | 2020-07-30 | 2023-04-11 | Arm Limited | Graphics processing systems |
-
2009
- 2009-10-16 US US12/580,250 patent/US20100112042A1/en not_active Abandoned
- 2009-10-16 CN CN200980148321.3A patent/CN102231979B/zh not_active Expired - Fee Related
- 2009-10-16 CA CA2739046A patent/CA2739046A1/en not_active Abandoned
- 2009-10-16 EP EP15153333.8A patent/EP2902013A1/en not_active Withdrawn
- 2009-10-16 JP JP2011532268A patent/JP2012505913A/ja active Pending
- 2009-10-16 AU AU2009305639A patent/AU2009305639B2/en not_active Ceased
- 2009-10-16 SG SG2014002885A patent/SG196818A1/en unknown
- 2009-10-16 EP EP09744527.4A patent/EP2349210B1/en not_active Not-in-force
- 2009-10-16 BR BRPI0920171A patent/BRPI0920171A2/pt not_active Application Discontinuation
- 2009-10-16 CN CN201410524574.9A patent/CN104382853A/zh active Pending
- 2009-10-16 KR KR1020117011136A patent/KR20110071017A/ko not_active Ceased
- 2009-10-16 WO PCT/US2009/060930 patent/WO2010045512A2/en not_active Ceased
-
2011
- 2011-03-29 ZA ZA2011/02319A patent/ZA201102319B/en unknown
- 2011-04-14 IL IL212329A patent/IL212329A0/en unknown
-
2012
- 2012-06-20 US US13/527,723 patent/US20130039970A1/en not_active Abandoned
-
2014
- 2014-12-11 JP JP2014251287A patent/JP6126072B2/ja active Active
-
2015
- 2015-04-09 US US14/682,314 patent/US20150209283A1/en not_active Abandoned
-
2016
- 2016-08-31 AU AU2016222371A patent/AU2016222371A1/en not_active Abandoned
-
2018
- 2018-06-25 AU AU2018204605A patent/AU2018204605A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012505913A5 (cg-RX-API-DMAC7.html) | ||
| US10760080B2 (en) | Anti-TNF compounds | |
| JP7753190B2 (ja) | 核酸の送達のための改善された脂質ナノ粒子 | |
| TWI495473B (zh) | 反義抗病毒化合物及治療流感病毒感染的方法 | |
| JP7699128B2 (ja) | ナノマテリアル | |
| AU2019361129A1 (en) | Lipids for lipid nanoparticle delivery of active agents | |
| EP3733647B1 (en) | Cationic lipid | |
| CN114716355B (zh) | 一种脂质化合物、包含其的组合物及应用 | |
| JP2015523853A (ja) | Ａｔｐ２ａ２発現を調節するための組成物及び方法 | |
| JP2015518713A (ja) | Ｕｔｒｎ発現を調節するための組成物及び方法 | |
| EP3336190B1 (en) | Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery | |
| CN109563509A (zh) | 靶向长非编码rna的减小尺寸的自递送核酸化合物 | |
| JP2015518711A (ja) | Ｂｄｎｆ発現を調節するための組成物及び方法 | |
| AU2016344384A1 (en) | Nanoparticle formulations for delivery of nucleic acid complexes | |
| JP2015518710A (ja) | ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法 | |
| CA3179824A1 (en) | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| JP2015523855A (ja) | Ａｐｏａ１及びａｂｃａ１発現を調節するための組成物及び方法 | |
| CN105658797A (zh) | 用于调节rna的组合物和方法 | |
| CN114073677B (zh) | 一种脂质纳米颗粒 | |
| WO2021257916A1 (en) | Una oligomers for the treatment of polyglutamine diseases | |
| WO2024207721A1 (zh) | 一种多尾型可电离脂质及其制备方法与应用 | |
| JP6774965B2 (ja) | カチオン性脂質としての化合物 | |
| CN104922070A (zh) | 含有天然薯蓣甾醇的阳离子脂质体、制备方法及其应用 | |
| CN118754949B (zh) | 一种多肽及其多肽复合物纳米粒、核酸疫苗和应用 | |
| Katas et al. | Bionanocomposites for RNAi-based delivery |